189 related articles for article (PubMed ID: 31400712)
1. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
Hou W; Zhang Y; Jin B; Cao W; Lu M; Yan L; Yang H; Tian X; Hou J; Fu J; Zhao H; Li H; Zhou J
Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
[TBL] [Abstract][Full Text] [Related]
3. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
Abla O; Ribeiro RC; Testi AM; Montesinos P; Creutzig U; Sung L; Di Giuseppe G; Stephens D; Feusner JH; Powell BL; Hasle H; Kaspers GJL; Dalla-Pozza L; Lassaletta A; Tallman MS; Locatelli F; Reinhardt D; Lo-Coco F; Hitzler J; Sanz MA
Ann Hematol; 2017 Sep; 96(9):1449-1456. PubMed ID: 28597167
[TBL] [Abstract][Full Text] [Related]
4. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
Chen X; Fan S; Zhao Y; Zhou J
Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia.
Xiao M; Zhou P; Liu Y; Wei S; Li D; Li W; Niu X; Niu J; Zhang Y; Cao W; Liu B; Wang X; Bai Y; Sun K
Thromb Res; 2022 Feb; 210():33-41. PubMed ID: 34998209
[TBL] [Abstract][Full Text] [Related]
6. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Hou J; Wang S; Zhang Y; Fan D; Li H; Yang Y; Ge F; Hou W; Fu J; Wang P; Zhao H; Sun J; Yang K; Zhou J; Li X
Ann Hematol; 2017 Dec; 96(12):2005-2013. PubMed ID: 28940056
[TBL] [Abstract][Full Text] [Related]
7. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
Zhao H; Zhao Y; Zhang Y; Hou J; Yang H; Cao F; Yang Y; Hou W; Sun J; Jin B; Fu J; Li H; Wang P; Ge F; Zhou J
Ann Hematol; 2018 Mar; 97(3):409-416. PubMed ID: 29289982
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
Singh C; Karunakaran P; Yanamandra U; Jindal N; Kumar SR; Saini N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Kumar N; Naseem S; Ahluwalia J; Varma N; Varma S; Malhotra P
Leuk Res; 2023 Nov; 134():107392. PubMed ID: 37774447
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
Wang Y; Hou W; Li H; Tian X; Li J; Hu T; Shi D; Zhang Y
Ann Hematol; 2022 May; 101(5):1039-1047. PubMed ID: 35174404
[TBL] [Abstract][Full Text] [Related]
11. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
[TBL] [Abstract][Full Text] [Related]
12. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ
Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
14. The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia.
Jillella AP; Kota VK
Blood Rev; 2018 Mar; 32(2):89-95. PubMed ID: 29033137
[TBL] [Abstract][Full Text] [Related]
15. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
16. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
17. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
18. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Chromosomal Karyotype on the Prognosis of Patients with Acute Promyelocytic Leukemia in Condition of the Maintenance Treatment Based on Arsenic Trioxide].
Lai BB; Mu QT; Zhang YL; Chen Y; Ouyang GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1380-1386. PubMed ID: 31607287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
